Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer

Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in... Key PointsQuestionDo anti–programmed cell death 1 and anti–programmed cell death ligand 1 deliver different clinical outcomes? FindingsIn this systematic review and meta-analysis of 19 randomized clinical trials involving 11 379 patients, anti–programmed cell death 1 appears to exhibit significantly greater overall survival compared with anti–programmed cell death ligand 1 with a comparable safety profile in patients with solid tumors. MeaningAnti–programmed cell death 1 appears to exhibit favorable survival outcomes and a comparable safety profile with anti–programmed cell death ligand 1 in cancer therapy, which may provide valuable insight for future treatment strategy. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Oncology American Medical Association

Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer

Loading next page...
 
/lp/american-medical-association/use-of-immunotherapy-with-programmed-cell-death-1-vs-programmed-cell-f67O0i4H0w
Publisher
American Medical Association
Copyright
Copyright 2019 American Medical Association. All Rights Reserved.
ISSN
2374-2437
eISSN
2374-2445
DOI
10.1001/jamaoncol.2019.5367
Publisher site
See Article on Publisher Site

Abstract

Key PointsQuestionDo anti–programmed cell death 1 and anti–programmed cell death ligand 1 deliver different clinical outcomes? FindingsIn this systematic review and meta-analysis of 19 randomized clinical trials involving 11 379 patients, anti–programmed cell death 1 appears to exhibit significantly greater overall survival compared with anti–programmed cell death ligand 1 with a comparable safety profile in patients with solid tumors. MeaningAnti–programmed cell death 1 appears to exhibit favorable survival outcomes and a comparable safety profile with anti–programmed cell death ligand 1 in cancer therapy, which may provide valuable insight for future treatment strategy.

Journal

JAMA OncologyAmerican Medical Association

Published: Mar 26, 2020

References